Clinical Trials Arena on MSN
Compass’ psilocybin shows six-month durability in Phase III trial
Compass has already submitted for approval of its psilocybin-based therapy to the FDA following previous Phase III success.
Compass Pathways plc upgraded to Strong Buy after phase 3 COMP360 TRD data & fast-track FDA NDA review; see catalysts, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results